Introduction
As patients with cystic fibrosis (CF) survive longer, certain pathogens are becoming more prevalent and important than previously recognized. Nontuberculous mycobacteria (NTM) have emerged over the last 20 years as important pathogens detected in the sputum of patients with CF. 1 However, it is not always straightforward recognizing whether the presence of NTM is contributing to the underlying disease process in patients with CF, and the commencement of treatment, which is prolonged and carries the risk of a number of sideeffects, should not be underestimated. The following case report highlights some of the challenges faced with the isolation of multiple strains of NTM in a patient with CF, and tries to address some of these difficulties. A 16- year-old boy was diagnosed with CF at the age of 2 years following confirmatory sweat testing (sweat chloride 110 mmol/L on two occasions) prompted by a series of respiratory tract infections. He was pancreatic sufficient with genotype delta F508/-. Genotype testing for 31 mutations did not yield a second mutation. Pseudomonas aeruginosa was isolated at the time of diagnosis and intermittently during early childhood as well as Staphylococcus aureus.
Case report
Up until the age of 8 years he had been relatively well and spirometry was stable with FEV 1 83% predicted. He had received three courses of intravenous antibiotics directed against pseudomonal infection. He was on long-term oral flucloxacillin prophylaxis and nebulized colomycin and gentamicin. There had not been any concerns regarding growth or nutritional status. At 9 years of age he first isolated NTM with a single isolate of Mycobacteria avium complex (MAC). He also isolated Staphylococcus aureus on one occasion during this period. Around this time his lung function started to decline and by the age of 10 years his FEV 1 had fallen to 67% predicted. He received courses of oral antibiotics directed against staphylococcal and pseudomonal infection, but without significant improvement. He had a persistent wet cough and breathlessness with reduced exercise tolerance. In the next 6 months he had three isolates of Mycobacteria chelonae (for sensitivities see Table 1 ) -with a continuing decline in lung function. He was smear positive on the first two occasions, and smear negative on the last isolate. He was admitted to hospital for intensive physiotherapy and intravenous antibiotics (ceftazidime and gentamicin). He had a transient improvement in clinical status and lung function, but this was not sustained. A CT of his chest was requested which showed evidence of widespread bronchiectasis (Figure 1 ).
His lung function continued to fall over the next few months ( Figure 2 ) and this prompted a further admission to hospital at just under 11 years of age. His FEV 1 had fallen to 45% predicted and symptomatically he had deteriorated again. A decision was made to undertake further investigations including flexible bronchoscopy, pH study and assessment of ABPA status. Bronchoalveolar lavage isolated M. chelonae and pH study was strongly positive (pH <4 for 23% study time) suggesting significant gastro-oesophageal reflux disease.
His allergic bronchopulmonary aspergillosis (ABPA) markers had been monitored since his diagnosis and throughout his deterioration. He did not isolate aspergillus species from his sputum and did not have convincing radiological features for ABPA. However, his IgE and aspergillus specific RAST were persistently elevated in the latter part of the first decade of life. At around 10 years of age his IgE was 939 IU/mL and aspergillus specific RAST 52.l IU/mL -both relatively stable. He had evidence of peripheral eosinophilia (2.4 × 10 9 /L) and co-existent symptoms suggestive of allergic rhinitis. Over the next 6 months his IgE rose further, although not markedly so (1241 IU/ mL) before beginning to decline spontaneously.
During his admission to hospital, he was commenced on a further three-week course of intravenous anti-pseudomonal antibiotics (ceftazidime and tobramycin). He was also started on treatment for gastro-oesophageal reflux disease and nebulized DNAse. Following this he improved clinically, his lung function improved (FEV 1 70% predicted) and over the next 7 months he remained relatively well.
However, this improvement was not sustained and by the age of 12 years his lung function had started to deteriorate and he had become more symptomatic. Various courses of antipseudomonal and anti-staphylococcal oral antibiotics did not lead to significant improvement in either lung function or clinical status. At just over 12 years of age he isolated M. abscessus for the first time, on two occasions (Table 1) . He was also smear positive. His lung function and clinical status remained poor with FEV 1 40% predicted. He was also exhibiting features of small airways disease. Attempts were made to improve both lung function and symptomatology with oral steroids (to try and ameliorate symptoms from small airways disease), nebulized tobramycin (TOBI), long-term azithromycin and montelukast -but with no effect. He was admitted to hospital and received a three-week course of intravenous antibiotics (meropenem and colomycin) -but remained breathless with poor exercise tolerance. He had an unremitting productive cough and episodes of haemoptysis. Lung function had not shown any improvement. Due to the poor response to treatment and the isolation of M. abscessus, a decision was made to commence anti-mycobacterial treatment with oral rifampicin (450 mg once daily), clarithromycin (250 mg twice daily) and ethambutol (600 mg once daily). He remained on this treatment for 18 months -during which time he improved significantly clinically and did not require any further courses of intravenous antibiotics during this period. His lung function improved to FEV 1 55% predicted. However, it did not improve further and he did not achieve spirometry values as high as he previously had done. Despite his clinical improvement he continued to isolate M. abscessus repeatedly from sputum samples and was intermittently smear positive.
When his anti-mycobacterial treatment was stopped 18 months later he once again deteriorated clinically. The following year he required a number of courses of oral antibiotics and two admissions to hospital for intravenous antibiotics (anti-pseudomonal and anti-staphylococcal). His Multiple strains of non-tuberculous mycobacteria in a patient with cystic fibrosis lung function, however, did not decline further and remained stable. He continued to isolate M. abscessus from sputum samples and remained intermittently smear positive. Due to his clinical decline, anti-mycobacterial oral treatment was re-commenced at the age of 15 years (rifampicin 600 mg once daily, clarithromycin 250 mg twice daily, ethambutol 800 mg once daily), with the addition of amikacin by nebulizer (500 mg twice daily). Unfortunately this was not enough to maintain good clinical status and by 16 years of age he had symptomatically deteriorated again. He was once more breathless with poor exercise tolerance and had a persisting productive cough with moderate episodes of haemoptysis. He was admitted to hospital for 3 weeks and received intravenous anti-pseudomonal antibiotics with limited benefit. After a brief period of time back at home he was readmitted to hospital a few weeks later due to further clinical decline. By this point his lung function had fallen once more to FEV 1 40% predicted and the episodes of haemoptysis were becoming more significant (blood count and coagulation profile normal). He had also developed fevers up to 40°C associated with rigors and moderately raised inflammatory markers (white cell count 13.1 × 10 9 /L, neutrophils 9.4 × 10 9 /L and CRP 108 mg/L). The only pathogen recovered continued to be M. abscessus on sputum samples, with intermittent smear positivity. Urine culture was negative and blood cultures, both peripherally and from his venous access device, did not isolate any pathogens. A CT of his chest was performed including angiography to exclude a pulmonary embolus ( Figure 3 ), but there was no evidence of this. The CT confirmed the presence of panlobar bronchiectasis. Although a diagnosis of NTM infection should not be based solely on radiological findings -there was no evidence of obvious NTM disease on the CT scan.
Due to his presenting features and the persistent isolation of M. abscessus he was initiated on intravenous treatment against NTM -cefoxitin (2 g four times a day), tigecycline (50 mg twice daily) and amikacin (30 mg/kg once daily). He was also commenced on nebulized meropenem (250 mg twice daily) while remaining on nebulized amikacin therapy and oral clarithromycin. He remained in hospital for a further three weeks on this treatment regime -before being discharged home to continue on oral ciprofloxacin (750 mg twice daily) and clarithromycin long-term as well as nebulized meropenem and amikacin. He remains stable and clinically improved -with FEV 1 static at 55% predicted. At present only M. abscessus continues to be isolated from sputum samples.
Discussion
This case highlights some of the challenges and difficulties associated with the management of isolates of NTM in patients with CF, and deciding at which stage to intervene with treatment which is prolonged, carries the risk of significant side-effects and adds to the burden of treatment for patients.
A number of other issues also appear unresolved. There was clinical improvement with therapy directed towards NTM -despite persistent isolation of M. abscessus. This raises the possibility that other pathogens were being treated by anti-NTM treatment. This case had isolates of S. aureus and P. aeruginosa earlier in childhood -and while these were not repeatedly isolated on sputum samples or cough swabs later in life, it is possible they were still present and contributing to his clinical status. It is known, for example, that anti-NTM treatment can have anti-staphylococcal actions (e.g. rifampicin).
This patient received a number of courses of azithromycin as well as the initiation of long-term single agent azithromycin (subsequently discontinued). It is recognized that single agent therapy with macrolides or azithromycin (an azalidestructurally similar to macrolides) can lead to NTM resistance. There was evidence of macrolide resistance in isolates of M. abscessus in this patient, which may have been present despite prior monotherapy. However, it does highlight this issue. He also received a three-month course of oral steroid treatment -which does have the potential to cause disseminated mycobacterial infection but did not do so in this patient.
It is possible that the significance of NTM is potentially underestimated in patients with CF. Although 'colonization' is a term used by some to describe the finding of NTM in the sputum of CF patients which is not thought to be causing disease, it is difficult to be certain that this is the case, and it is unclear what impact NTM may have on the CF lung.
It remains plausible that in this case the initial isolates of M. chelonae and subsequent M. abscessus were having more of a clinical impact than initially thought -and it is possible that with earlier intervention his lung function may not have declined as significantly. However, there are a number of other possibilities for his decline including significant bronchiectatic changes in his lungs and the potential for other confounding factors (e.g. other pathogens, gastro-oesophageal reflux disease). He also did not show overwhelming evidence of NTM on chest-imaging. The potential for toxicity from anti-NTM treatment, and the commitment to long-term therapy once started, should not be underestimated. Taking into account the 2007 American Thoracic Society (ATS) NTM guidelines, which state that part of the criteria for confirmation of NTM infection is the exclusion of other diagnoses, it is easy to see how difficult this can be in a patient with CF.
Non-tuberculous mycobacteria in CF
Over the last 20 years, with the increasing survival of patients with CF, a number of pathogens are emerging which are generally not seen in younger patients with CF and had not been encountered previously. 1 Included in this group of pathogens are NTM, of which there are currently thought to be more than 140 species. 2 The number of species identified has increased significantly over the past few years -not all of which are thought to be pathological in humans. However, this rapid increase in identified species highlights the improvements in microbiological techniques (including 16S rRNA gene sequencing) that have enabled greater classification of NTM species, and separation of closely-related species (e.g. Mycobacteria chelonae and Mycobacteria abscessus). 3 NTM are environmental pathogens found throughout the world particularly in soil and water (including domestic water supplies). They
Multiple strains of non-tuberculous mycobacteria in a patient with cystic fibrosis are aerobic, non-motile bacilli that stain positively for acid-alcohol fastness. 3 There has not been any evidence of animal-to-human or human-to-human transmission of NTM, including no evidence of cross-infection between patients with CF. Outbreaks have, however, been described following the use of disinfected equipment on patients -presumed either through inadequate cleaning, or from the water supply used to perform the disinfection process -although the exact source is often never identified. 4, 5 NTM were first recognized as causing disease in humans in the 1950s. However, by the 1990s only 16 case reports existed in the literature of NTM infection in patients with CF. 6 NTM are known to have a predilection for causing disease in patients with underlying medical conditions which predispose them to infection. As well as CF, this includes patients with other lung conditions such as bronchiectasis and primary ciliary dyskinesia. 4
Important NTM species in CF
The commonest NTM species seen in patients with CF include Mycobacteria avium complex (MAC), Mycobacteria abscessus, Mycobacteria chelonae and Mycobacteria kansasii. The exact prevalence of NTM in patients with CF varies widely between centres. One study has quoted a prevalence range of 7-24% in CF centres in the USA, and appears to be correlated with increasing age. The commonest NTM species found in these patients were MAC and M. abscessus. Those with M. abscessus infection were also more likely to meet ATS criteria for NTM disease. 1 In studies, MAC and M. abscessus appear to be the most common species in CF -and for this reason this article will focus on these two species.
MAC includes at least two mycobacterial species: Mycobacteria avium and Mycobacteria intracellulare, which can only be differentiated by specific DNA probes. This is not routinely carried out as there are not thought to be any prognostic differences between the two species, and treatment remains the same for both. The prognosis and management of MAC is similar in patients both with and without CF. 4 Mycobacteria abscessus is often more difficult to treat than other NTM species, due to antibiotic resistance, and has been associated with significant clinical deterioration in patients with CF in some case reports. 8 However, there are mixed views on this. Other reports have suggested a protracted course of NTM infection, without clinical decline, and a recent cohort study has shown that over a 15-month period, CF patients both with and without NTM infection showed no difference in imaging findings or spirometry values. 9
Identifying CF patients at risk of NTM infection NTM are known to have a predilection for causing disease in patients with underlying medical conditions which predispose them to infectionincluding underlying lung disease. Patients with CF have altered mucociliary clearance and increased airway mucus, which may predispose them to infection with NTM. 10 Patients with other lung conditions such as bronchiectasis and primary ciliary dyskinesia also seem to have a predisposition to NTM infection. 11 It is difficult to know whether bronchiectasis is due to or a contributing factor towards NTM infection. Studies have provided conflicting results as to the CF patient groups most at risk of NTM infection. A study of CF patients in the UK in 1998 found that those who isolated NTM tended to be those having more frequent courses of intravenous antibiotics, implying this was a group with more severe lung disease. 12 However, a more recent multicentre study in the USA found that CF patients isolating NTM tended to have better lung function. These patients (and especially those that met ATS criteria for infection) also tended to isolate Staph aureus and not Pseudomonas aeruginosa. 1 This could potentially be a reflection of lower levels of P. aeruginosa -thus allowing NTM to grow on media; or a reflection of milder lung disease. There is a positive association between NTM infection and age of CF patients. 13 Concern exists about the use of steroid therapy in patients with NTM infection, as there is an increased risk of developing disseminated NTM infection. There are anecdotal reports of the development of severe NTM lung disease in patients treated with steroids for ABPA. 14 There is some evidence to suggest elderly patients without predisposing lung disease and NTM infection have an increased incidence of CF gene mutations -suggesting a possible role for this in the underlying susceptibility of CF patients to NTM infection. 15 
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Making a diagnosis of NTM infection in patients with CF
Determining the significance of an isolate of NTM in a respiratory sample from a patient with CF is not always straightforward. Isolation of NTM per se does not necessarily imply disease -and may merely reflect colonization or potentially environmental contamination. The American Thoracic Society (ATS) has produced extensive guidelines for the management of NTM in patients (Table 2) , although not limited to those with CF. These guidelines are thought to best represent infection with Mycobacteria avium complex, Mycobacteria kansasii and Mycobacteria abscessus, as knowledge of other NTMs is insufficient to be certain that these criteria apply to all NTM species. 3 Clearly in a patient with an underlying chronic lung disease such as CF, it can be extremely difficult to prove that the isolation of NTM is contributing to the underlying pathological process. This can be for a variety of reasons, including potential difficulties acquiring the required number of positive sputum samples in CF patients, due to overgrowth of P. aeruginosa in sputum samples. Different decontamination techniques have been utilized to try and aid the culture of NTM in sputum samples. 16 Radiographical changes are non-specific and can be difficult to interpret on a background of severe imaging changes from the underlying disease. Certain radiological characteristics are felt to be more representative of NTM infection -such as cavitating lesions, nodules and tree-in-bud appearances. 17 However, the diagnosis should not be based on imaging findings alone.
Pulmonary symptoms can be extremely nonspecific, including cough, breathlessness, haemoptysis and a decline in lung function -all of which can be seen in CF patients with a conventional bacterial exacerbation. Patients with NTM infection may also have night sweats and fevers, which are not generally seen in typical CF respiratory exacerbations. However, these are not seen in the majority of patients with NTM infection. This, therefore, makes the 'exclusion of other diagnoses' quite difficult and challenging in patients with CF. However, as a minimum, patients with CF and potential NTM infection should have at least three sputum samples sent, appropriate imaging and consideration as to whether there are other untreated factors leading to respiratory deterioration. 4
Collection of samples
Current recommendations are that patients with CF should have sputum cultured routinely on an annual basis looking specifically for NTM. Sputum samples for NTM should also be sent on any patient with CF showing an unexplained respiratory deterioration. In patients who do not expectorate sputum and who exhibit unexplained clinical deterioration, it may be appropriate to obtain samples via bronchoscopy and bronchoalveolar lavage. Transbronchial or lung biopsy is not routinely undertaken in order to diagnose NTM infection in patients with CF. However, if samples are obtained for other reasons, they should be sent for NTM culture. 4
Treatment
Prior to commencing treatment patients should be formally assessed and baseline chest imaging obtained -usually a CT scan. Serial sputum samples should be obtained prior to and throughout treatment. 4 Not all patients with CF who isolate NTM require treatment, as many will not meet criteria for NTM disease. However, these patients should be monitored closely -and treatment considered if there is clinical deterioration, provided other potential causes for clinical decline have been addressed. This includes the appropriate Multiple strains of non-tuberculous mycobacteria in a patient with cystic fibrosis treatment of other pathogens -as anti-NTM treatment will also potentially treat other bacterial species such as Staph aureus, making assessment of response to treatment more difficult to assess.
There is increasing use of azithromycin as an immunomodulating drug in CF. There is also evidence to suggest that single agent therapy with macrolides or azithromycin leads to the development of macrolide-resistant NTM. 16 It is, therefore, important to ensure that patients do not have evidence for NTM on sputum samples before treatment is commenced.
It is important to remember that anti-NTM drugs have a variety of potential side-effects, and may interact with medications that the patient with CF is already taking. It is particularly important to be aware of these issues in patients with CF liver disease.
The decision to treat NTM in a patient with CF, and the choice of drugs used, should be directed by a physician with experience in treating the condition, in liaison with a microbiologist. The following treatment regimes are adapted from the 2007 ATS NTM guidelines. 4
Mycobacteria avium complex
Generally it is not considered necessary to identify whether the isolate is Mycobacteria avium or Mycobacteria intracellulare. Treatment and response to treatment against MAC is similar for patients both with and without CF. An initial treatment regime suggested by the 2007 ATS guidelines includes the combination of a macrolide such as clarithromycin, ethambutol and rifampicin. The reader should refer to these guidelines for further clarification on dosing, as this depends on disease severity. For cavitatory disease a suggested regime is clarithromycin 500 mg to 1000 mg once daily, ethambutol 15 mg/kg once daily and rifampicin 450-600 mg once daily. 4 It should be remembered that these guidelines are not specific for CF or children, and many of the doses utilized by CF centres in these patients are based on anecdotal evidence. It is recommended that liaison takes place with a clinician experienced in treating such patients, before the commencement of medication. For patients who are more unwell, or with significant cavitatory disease, treatment may need to include an intravenous agent such as amikacin (ATS guidelines quote a dose of 10-15 mg/kg once daily, but this is not specific to CF patients. A dose of 30 mg/kg once daily is used in CF patients at the Royal Brompton Hospital, with monitoring of levels). Macrolides should not be used as monotherapy due to the risk of developing macrolide resistance. The aim of treatment is eradication of MAC from sputum for 12 months while the patient is on treatment. Treatment is, therefore, needed for a minimum of a year. Failure to respond to treatment should be discussed with an experienced physician and microbiologist. 4, 18 
Mycobacteria abscessus
Mycobacteria abscessus and Mycobacteria chelonae were previously included as the same species. Improvements in laboratory techniques have enabled the identification of individual species, which is important as treatment of M. chelonae is often easier than M. abscessus. Other means of helping to identify species include antibiotic sensitivity -for example M. abscessus is often sensitive to cefoxitin, whereas M. chelone is nearly always resistant.
Treating Mycobacteria abscessus can be difficult as it is generally fairly resistant to most anti-NTM drugs. Isolates can also acquire resistance to clarithromycin and amikacin -through gene mutations. This is because M. abscessus has only one copy of the genes 23S rRNA and 16s rRNA, which confer susceptibility to clarithromycin and amikacin, respectively. 19 Choice of treatment regime will be dictated to some extent by disease severity and antibiotic susceptibilities. Treatment regimes usually include a macrolide, such as clarithromycin (with dosing up to 1000 mg once daily or in divided doses -although gastrointestinal sideeffects may limit the dose tolerated), and intravenous therapy. 4 Monotherapy with a macrolide is not recommended due to the risk of developing macrolide resistance. Of the intravenous drugs available, the combination of amikacin (see dosing recommendations for MAC) and cefoxitin (up to 12 g/day in divided doses) 4 has been utilized in CF patients with M. abscessus disease. More recently tigecycline (a tetracycline derivative) has been added into the intravenous combination of drugs. In adult and adolescent CF patients at the Royal Brompton we have used doses of 50 mg every 12 hours. Again care should be taken with smaller paediatric patients and expert advice sought. Tigecycline is often poorly tolerated and leads to significant nausea. This can be limited to some extent by co-administration of anti-emetics. A reasonable proportion of M. abscessus isolates are sensitive to linezolid (doses up to 600 mg twice daily) -an oral oxazolidinone. Many patients are also commenced on nebulized antibiotics such as meropenem or amikacin. Evidence for dosing is mainly anecdotal (nebulized meropenem 250 mg twice daily and nebulized amikacin 500 mg twice daily used at the Royal Brompton). There are also suggestions that interferon gamma treatment may be helpful in some patients, particularly those with an impaired IL-12/interferon gamma axis which is needed for immune regulation of mycobacterial infections. 4, 18, 20 The first trial of treatment for patients with M. abscessus infection was recently published. This looked at 65 patients with M. abscessus infection who did not have CF. Patients received clarithromycin (1000 mg/day), ciprofloxacin (1000 mg/ day) and doxycycline (200 mg/day) together with an initial regime of four weeks of intravenous amikacin (15 mg/kg/day in two divided doses) and cefoxitin (200 mg/kg/day -maximum dose 12 g/day in three divided doses). Oral treatment was given for a total of 24 months, and was continued for at least 12 months after sputum culture conversion. Symptoms improved in over 80% of patients and CT findings were reported to improve in 74%. Fifty-eight percent of patients were reported to become culture negative and to remain culture negative for a year. The main problem encountered was medication toxicity. 22 Ultimately for many patients, both with and without CF, eradication of M. abscessus is not possible. The mainstay of treatment is, therefore, amelioration of symptoms. Length of treatment is variable -and many patients are continued on long-term oral therapy -with combinations of a macrolide and another drug such as ciprofloxacin or an oral tetracycline, in age-appropriate patients, depending on sensitivities. Length of linezolid therapy is limited by side-effects such as peripheral and optic neuropathy, which are more likely to become apparent after around 28 days of treatment. Linezolid treatment also requires blood count monitoring, due to the risk of developing haematopoietic disorders.
Intravenous therapy can be required for weeks or months, depending on the response and tolera-tion of toxicity. There is evidence to suggest that nebulized amikacin and/or meropenem can be helpful in keeping M. abscessus infection under control, even if not eradicating it.
In some cases of M. abscessus infection, surgical treatment may be contemplated. However, this is only considered if there is localized disease amenable to resection and should only be considered in extreme circumstances in patients with CF; and only carried out in centres with considerable experience in this area. 23
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+ Clarithromycin -level decreased by rifampicin /increased by antifungals such as itraconzole.
Gastrointestinal side-effects + Rifampicin -potential liver toxicity and induction of liver enzymes (may affect levels of other drugs). Stains secretions and urine orange + Linezolid -optic and peripheral neuropathy.
Haematopoietic disorders + Ethambutol -monitor visual acuity + Cefoxitin -ototoxicity/renal toxicity/blood dyscrasias + Tigecycline -vomiting/nausea + Amikacin -ototoxicity/renal toxicity + Isoniazid -potential liver toxicity Transplantation A significant proportion of CF patients with endstage disease being considered for lung transplantation have evidence of NTM infection. A recent study of pre-transplant CF patients showed around 20% had evidence of NTM infection and around 14% had evidence of NTM pulmonary infection post-transplantation. The source of posttransplantation NTM was presumed to be from the remaining native airway in these patients, above the area of anastomosis. There were no reports of the transplanted lung showing evidence of NTM infection pre-transplantation. 24 There had previously been reluctance to perform lung transplantations in patients with evidence of NTM infection, but this opinion has changed in recent years and the presence of NTM Multiple strains of non-tuberculous mycobacteria in a patient with cystic fibrosis infection is no longer considered to be an absolute contraindication. However, there are a number of considerations to be made in these patients. Following transplantation a number may develop NTM infection in the transplanted lung. As patients following transplantation need to take a number of immunosuppressive agents, there is the significant risk of disseminated NTM infection. The above study has shown the prevalence of invasive NTM infection following transplantation to be relatively low at 3.4%. This was linked to pre-transplant NTM isolation and in particular M. abscessus infection. Although there was considerable difficulty in managing these patients, they were reported to be successfully treated and did not have increased mortality compared to those patients without evidence of NTM infection. 24 However, this is not a universal finding, and there are case reports in the literature of patients dying from invasive NTM disease (particularly M. abscessus) post-transplantation. 25 Thus careful consideration of each case is merited prior to transplantation, and in particularly in the case of M. abscessus, treatment commenced and an attempt at eradication prior to contemplation of transplantation. There is also some evidence to suggest that being smear positive, as well as culture positive, for NTM confers an increased risk of disseminated disease post-transplantation. 24, 25 
Conclusions
The effect of NTM on CF lung disease is still poorly understood, and predicting those patients that would benefit from treatment remains a challenging area of CF management. However, as survival continues to improve in patients with CF, the presence of NTM as an important group of pathogens will require more focus. Current treatment and management follows the ATS criteria for identifying patients with NTM disease. However, as discussed, these criteria are not easily applied to patients with CF and there are no specific guidelines on treatment in patients with CF. In particular M. abscessus remains a significant challenge with varying reports in the literature of catastrophic decline as well as periods of prolonged clinical stability. The challenge for the future is identifying those patients at risk of such decline, understanding the reasons for this and improving overall management and therapies available.
